It is evident that lysosomal dysfunction in MPS I can impact the release and secretion of CTSB, influencing the pathophysiological progression of cardiovascular lesions in MPS I. Targeting CTSB could present a novel avenue for future therapeutic interventions in MPS I‐related cardiovascular complications. This evidence concerns the gene CTSB and Scheie syndrome.